Total Voting Rights

May 1, 2014

Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following: 

At close of business on April 30, 2014, the Company’s issued ordinary share capital comprised 589,014,068 ordinary shares of 5 pence each with voting rights and a further 9,019,832 ordinary shares held in treasury. 

Therefore the total number of voting rights in the Company is 589,014,068. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. 

Tony Guthrie

Deputy Company Secretary

 

For further information please contact:

Investor Relations            

Jeff Poulton   
jpoulton@shire.com
+1 781 482 0945

Eric Rojas    
erojas@shire.com
+1 781 482 0999

Sarah Elton-Farr    
seltonfarr@shire.com
+44 1256 894157

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

www.shire.com

Click here for the PDF version of this press release.